Cited by 62HIV-related health complications and treatmentsHIV/AIDS Research and InterventionsHIV, Drug Use, Sexual Risk

Projecting 10-year, 20-year, and Lifetime Risks of Cardiovascular Disease in Persons Living With Human Immunodeficiency Virus in the United States

Open access
Losina, Elena, Hyle, Emily P, Borre, Ethan D, Linas, Benjamin P, Sax, Paul E, Weinstein, Milton C, Rusu, Corinna, Ciaranello, Andrea L +2 more·2017·Clinical Infectious Diseases

Abstract

Background: Cardiovascular disease (CVD) is an increasing cause of morbidity among persons living with human immunodeficiency virus (HIV; PLWH). We projected cumulative CVD risk in PLWH in care compared to the US general population and persons HIV-uninfected, but at high risk for HIV. Methods: We used a mathematical model to project cumulative CVD incidence. We simulated a male and female cohort for each of 3 populations: US general population; HIV-uninfected, at high risk for HIV; and PLWH. We incorporated the higher smoking prevalence and increased CVD risk due to smoking into the HIV-infected and HIV-uninfected, at high risk for HIV populations. We incorporated HIV-attributable CVD risk, independent of smoking. Results: For men, life expectancy ranged from 70.2 to 77.5 years and for women from 67.0 to 81.1 years (PLWH, US general population). Without antiretroviral therapy, lifetime CVD risk for HIV-infected males and females was 12.9% and 9.0%. For males, by age 60, cumulative CVD incidence was estimated at 20.5% in PLWH in care, 14.6% in HIV-uninfected high-risk persons, and 12.8% in the US general population. For females, cumulative CVD incidence was projected to be 13.8% in PLWH in care, 9.7% for high-risk HIV-uninfected persons, and 9.4% in the US general population. Lifetime CVD risk was 64.8% for HIV-infected males compared to 54.8% for males in the US general population, but similar among females. Conclusions: CVD risks should be a part of treatment evaluation among PLWH. CVD prevention strategies could offer important health benefits for PLWH and should be evaluated.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/cix547

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • HAART does not protect patients from persistent immune activation, chronic inflammation, and excess risk of developing CVD and frailty.

    “However, this therapy does not protect patients from the persistent immune activation, chronic inflammation, and excess risk of developing CVD and frailty131–135.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 45 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Losina, E., Hyle, E. P., Borre, E. D., Linas, B. P., Sax, P. E., Weinstein, M. C., Rusu, C., Ciaranello, A. L., Walensky, R. P., & Freedberg, K. A.
Affiliations
  • Boston University (US)
  • Massachusetts General Hospital (US)
  • Brigham and Women's Hospital (US)
  • Harvard University (US)
Corresponding author
Losina, Elena
Venue
Clinical Infectious Diseases
Published
2017-06-12
Volume
65
Issue
8
Pages
1266-1271
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2625907129
Cited by
62
References
45
Citations by year
2026: 4 · 2025: 4 · 2024: 6 · 2023: 7 · 2022: 5 · 2021: 11 · 2020: 3 · 2019: 6 · 2018: 10 · 2017: 5
FWCI
8.34
Type
journal article
Language
en
Open access
Locations
  • Clinical Infectious Diseases (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
NIH (R01 AI042006, T32 AI007433, K01 HL123349, R01 DA031059, P30 DA040500, P30 AI069354, P30 AI042853)
Topics
  • Health Sciences › Medicine › Emergency Medicine › HIV-related health complications and treatments
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
  • Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
Keywords
cardiovascular disease, HIV, lifetime cardiovascular risk, smoking, antiretroviral therapy, cardiovascular disease prevention, life expectancy, sex differences
MeSH terms
Adult, Aged, Cardiovascular Diseases, Female, Humans, Life Expectancy, Male, Middle Aged, Risk Factors, Smoking, Models, Statistical, HIV Infections, Incidence, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review